Pura Vida Investments

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 31
Average round size
info
The average size of a deal this fund participated in
$106M
Portfolio companies 24
Rounds per year 3.10
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.23
Exits 8
Key employees 2
Stages of investment
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Medical Device
  • Health Diagnostics
Summary

In 2012 was created Pura Vida Investments, which is appeared as VC. The main office of represented VC is situated in the New York. The company was established in North America in United States.

The high activity for fund was in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. Considering the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations.

Among the most popular fund investment industries, there are Pharmaceutical, Health Care. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Acutus Medical, MedAvail, V-Wave. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The standard case for the fund is to invest in rounds with 7-8 partakers. Despite the Pura Vida Investments, startups are often financed by Pontifax, OrbiMed, GE Ventures. The meaningful sponsors for the fund in investment in the same round are Triventures, Redmile Group, Pontifax. In the next rounds fund is usually obtained by Deerfield Capital Management, Triventures, Royalties Fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Pura Vida Investments:
Typical Co-investors
Pura Vida Investments is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Pura Vida Investments:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ABC-CLIO Corporate -
Alpha Partners New York, New York, United States
Beijing Fucheng Gangjian Touzi Beijing, Beijing, China
e4e California, Santa Clara, United States
Fil Rouge Capital (FRC) Croatia, Grad Zagreb, Zagreb
GB Group Cheshire, Chester, United Kingdom
GO4IT Brazil, Rio de Janeiro, Rio De Janeiro
HLM Property Management England, London, United Kingdom
Huize Tianxia Chengdu Shi, China, Sichuan
IT Forest Corporation Japan, Tokyo
New England Clean Energy Council Boston, Massachusetts, United States
Premier Charlotte, North Carolina, United States
Rosemoor Capital Management LLC New York, New York, United States
Shenzhen Woer Heat-Shrinkable Material China, Guangdong Province, Pingshan District
SP Capital Central, Central Region, Singapore
Viventures California, San Mateo, United States
Yingkai Luyi Touzi China, Ningbo, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Lyra Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
Wellness
$100M08 Apr 2022 Massachusetts, United States

Nalu Medical

Health Care
Medical
Medical Device
$104M17 Feb 2022 Carlsbad, California, United States

Greenlight Biosciences

Agriculture
AgTech
Biotechnology
Chemical
Fuel
Sustainability
$125M03 Feb 2022 Massachusetts, United States

Metagenomi

Artificial Intelligence
Machine Learning
$175M25 Jan 2022 California, United States

Freenome

Biotechnology
Health Care
Health Diagnostics
Personal Health
$300M07 Dec 2021 South San Francisco, California, United States

NanoMosaic

Biopharma
Biotechnology
Genetics
Health Diagnostics
Therapeutics
$40M06 Dec 2021 Woburn, Massachusetts, United States

SLANG Worldwide

Cannabis
Consumer Goods
Packaging Services
$17M16 Nov 2021 Toronto, Ontario, Canada

Science 37

Biotechnology
Clinical Trials
Health Care
Mobile
$200M07 Oct 2021 Los Angeles, California, United States

Exo

Health Care
Medical
Medical Device
$220M29 Jul 2021 Redwood City, California, United States
News
Exo secures $200M toward commercializing ultrasound device

– Exo, a handheld ultrasound device and point-of-care workflow platform, raised $220m funding.
– The round was led by RA Capital Management and joined by BlackRock, Sands Capital, Avidity Partners, Pura Vida Investments and prior investors.
– The company plans to use the funding to commercialize its device and to build out its informatics platform.

Ultivue Announces $50M Financing Round

– Ultivue announced the completion of a $50m Series D round of financing.
– New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners.
– Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.
– This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Pura Vida Investments?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: